Longeveron (LGVN) Cash from Financing Activities (2020 - 2026)

Longeveron's (LGVN) quarterly Cash from Financing Activities came in at $15.5 million in Q1 2026, up 26801.72% year-on-year from N/an in Q1 2025, and up 1893.18% quarter-over-quarter from $777000.0 in Q4 2025.

Longeveron (LGVN) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Longeveron's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $15.5 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 26801.72% year-over-year to $15.5 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 29.49% decrease from a year earlier, with the FY2025 full-year figure at $4.7 million, down 83.78% from the prior year.
  • Cash from Financing Activities rose to $15.5 million in Q1 2026 per LGVN's latest filing, from $777000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $15.5 million in Q1 2026 and bottomed at -$193000.0 in Q4 2022.
  • The 5-year median for Cash from Financing Activities is -$27000.0 (2022), against an average of $3.2 million.
  • Across the five-year window, Cash from Financing Activities sank 678.95% in 2022 and surged 27548.0% in 2024, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$193000.0 in 2022, then soared by 2905.7% to $5.4 million in 2023, then slumped by 100.92% to -$50000.0 in 2024, then surged by 1654.0% to $777000.0 in 2025, then soared by 1893.18% to $15.5 million in 2026.
  • Per Business Quant, the three latest LGVN Cash from Financing Activities figures stand at $15.5 million (Q1 2026), $777000.0 (Q4 2025), and $4.1 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 15.49 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 15.49 Mn
Mar 31, 2026 15.49 Mn
Dec 31, 2025 777,000.00
Dec 31, 2025 777,000.00
Sep 30, 2025 4.08 Mn
Sep 30, 2025 4.08 Mn
Jun 30, 2025 -133,000.00
Jun 30, 2025 -133,000.00
Mar 31, 2025 -58,000.00
Mar 31, 2025 -58,000.00
Dec 31, 2024 -50,000.00
Dec 31, 2024 -50,000.00
Sep 30, 2024 13.72 Mn
Sep 30, 2024 13.72 Mn
Jun 30, 2024 15.05 Mn
Jun 30, 2024 15.05 Mn
Mar 31, 2024 63,000.00
Mar 31, 2024 63,000.00
Dec 31, 2023 5.42 Mn
Dec 31, 2023 5.42 Mn